These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 9595973)

  • 1. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG).
    Rudick RA; Simonian NA; Alam JA; Campion M; Scaramucci JO; Jones W; Coats ME; Goodkin DE; Weinstock-Guttman B; Herndon RM; Mass MK; Richert JR; Salazar AM; Munschauer FE; Cookfair DL; Simon JH; Jacobs LD
    Neurology; 1998 May; 50(5):1266-72. PubMed ID: 9595973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
    Herndon RM; Rudick RA; Munschauer FE; Mass MK; Salazar AM; Coats ME; Labutta R; Richert JR; Cohan SL; Genain C; Goodkin D; Toal M; Riester K
    Mult Scler; 2005 Aug; 11(4):409-19. PubMed ID: 16042223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients.
    Cook SD; Quinless JR; Jotkowitz A; Beaton P;
    Neurology; 2001 Sep; 57(6):1080-4. PubMed ID: 11571337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
    Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
    J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.
    Bertolotto A; Malucchi S; Sala A; Orefice G; Carrieri PB; Capobianco M; Milano E; Melis F; Giordana MT
    J Neurol Neurosurg Psychiatry; 2002 Aug; 73(2):148-53. PubMed ID: 12122172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.
    Sorensen PS; Koch-Henriksen N; Ross C; Clemmesen KM; Bendtzen K;
    Neurology; 2005 Jul; 65(1):33-9. PubMed ID: 15888603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS.
    Francis GS; Rice GP; Alsop JC;
    Neurology; 2005 Jul; 65(1):48-55. PubMed ID: 16009884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Rudick RA; Goodkin DE; Jacobs LD; Cookfair DL; Herndon RM; Richert JR; Salazar AM; Fischer JS; Granger CV; Simon JH; Alam JJ; Simonian NA; Campion MK; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Whitham RH
    Neurology; 1997 Aug; 49(2):358-63. PubMed ID: 9270562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.
    Antonelli G; Simeoni E; Bagnato F; Pozzilli C; Turriziani O; Tesoro R; Di Marco P; Gasperini C; Fieschi C; Dianzani F
    J Neurol Sci; 1999 Oct; 168(2):131-6. PubMed ID: 10526196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive.
    Myhr KM; Ross C; Nyland HI; Bendtzen K; Vedeler CA
    Neurology; 2000 Nov; 55(10):1569-72. PubMed ID: 11094118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
    Massart C; Gibassier J; de Seze J; Debouverie M; Moreau T; Pelletier J; Vermersch P; Edan G
    Clin Chim Acta; 2008 May; 391(1-2):98-101. PubMed ID: 18249193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic impact of interferon antibodies, and complexities in assessing their clinical significance.
    Rudick RA
    Neurology; 2003 Nov; 61(9 Suppl 5):S31-4. PubMed ID: 14610110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.
    Vallittu AM; Halminen M; Peltoniemi J; Ilonen J; Julkunen I; Salmi A; Erälinna JP;
    Neurology; 2002 Jun; 58(12):1786-90. PubMed ID: 12084878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case study on the effect of neutralizing antibodies to interferon beta 1b in multiple sclerosis patients followed for 3 years with monthly imaging.
    Chiu AW; Ehrmantraut M; Richert ND; Ikonomidou VN; Pellegrini S; McFarland HF; Frank JA; Bagnato F
    Clin Exp Immunol; 2007 Oct; 150(1):61-7. PubMed ID: 17666095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serial immunoprecipitation assays for interferon--(IFN)-beta antibodies in multiple sclerosis patients.
    Lampasona V; Rio J; Franciotta D; Furlan R; Avolio C; Fazio R; Lavolpe V; Vincent A; Comi G; Trojano M; Montalban X; Martino G
    Eur Cytokine Netw; 2003; 14(3):154-7. PubMed ID: 14656689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
    Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?
    Sorensen PS; Koch-Henriksen N; Flachs EM; Bendtzen K
    Mult Scler; 2008 Jul; 14(6):837-42. PubMed ID: 18505772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study.
    Pachner AR; Warth JD; Pace A; Goelz S;
    Neurology; 2009 Nov; 73(18):1493-500. PubMed ID: 19884577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.